Systemic Lupus Erythematosus Related Interstial Lung Disease
Conditions
Brief summary
assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .
Detailed description
for all patients detailed history taken clinical and rhumatological examination will be assessed and SLEDAI score will be collected from the case record of the patients&laboratory investigation included 1\_erythrocytic sedimentation rate.2\_complete blood count.3\_interleukin23 .4\_complement 3&4.5\_Antinuclear Antibodies.6\_Anti double stranded antibodies.7\_full basic biochemical test(24 urine protien)8\_high resolution computed tomography.
Interventions
BIOLOGICALinterleukin 23
assessment of interleukin 23 in Sera of patients using ELIZA
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.
Exclusion criteria
* patients with chest conditions rather than interstial lung disease &who receiving biological blocking antibodies& those treated with immunosuppressive drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| interleukin 23 | 2 years | level of interleukin 23 in Sera of patients with systemic lupus erythematosus using ELIZA |
Countries
Egypt
Contacts
Primary ContactKhadiga M Salem, resident doctor
Outcome results
None listed